Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes

Death and anti-death: tumour resistance to apoptosis

2002 • 1,963 citations

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

1996 • 1,281 citations

Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule

1994 • 1,120 citations

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

2002 • 1,014 citations

Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

1996 • 917 citations

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

1996 • 894 citations

Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity

1998 • 789 citations

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

1998 • 781 citations

Downregulation of Fas ligand by shedding

1998 • 681 citations

The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis

2001 • 677 citations

Expression of the functional soluble form of human fas ligand in activated lymphocytes.

1995 • 656 citations

Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

1993 • 643 citations

MHC class I antigens, immune surveillance, and tumor immune escape

2003 • 475 citations

Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing.

1995 • 398 citations

A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.

1993 • 383 citations

Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.

2001 • 365 citations

The Fas Counterattack In Vivo: Apoptotic Depletion of Tumor-Infiltrating Lymphocytes Associated with Fas Ligand Expression by Human Esophageal Carcinoma

1998 • 331 citations

The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis

2001 • 327 citations

Somatic Fas Mutations in Non-Hodgkin’s Lymphoma: Association With Extranodal Disease and Autoimmunity

1998 • 324 citations

HLA class I antigen abnormalities and immune escape by malignant cells

2002 • 264 citations

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

2000 • 256 citations

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.

1998 • 238 citations

Mutations in the Fas Antigen in Patients With Multiple Myeloma

1997 • 228 citations

Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

2001 • 203 citations

An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.

1996 • 199 citations

Non-apoptotic Fas signaling

2002 • 191 citations

Mutations in the Fas Antigen in Patients With Multiple Myeloma

1997 • 183 citations

Activation‐induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack

2002 • 154 citations

Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

1996 • 142 citations

Alterations of Fas (Apo-1/CD95) Gene in Cutaneous Malignant Melanoma

1999 • 136 citations

Fas-Mediated Suicide of Tumor-Reactive T Cells Following Activation by Specific Tumor: Selective Rescue by Caspase Inhibition

1999 • 126 citations

Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

2000 • 102 citations

Association of HLA class I and class II antigen expression and mortality in uveal melanoma.

2001 • 100 citations

FasL:Fas ratio--a prognostic factor in breast carcinomas.

2000 • 99 citations

Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.

1986 • 96 citations

Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.

2001 • 84 citations

FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas

1999 • 83 citations

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma

2000 • 77 citations

Fas counter-attack–the best form of tumor defense?

1999 • 74 citations

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms

2000 • 73 citations

The Clonal Composition of a Peptide-Specific Oligoclonal CTL Repertoire Selected in Response to Persistent EBV Infection Is Stable Over Time

1998 • 67 citations

Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancerin vivo

2000 • 41 citations

Rejection of Intraocular Tumors by CD4+ T Cells Without Induction of Phthisis

2001 • 32 citations

Somatic Fas Mutations in Non-Hodgkin’s Lymphoma: Association With Extranodal Disease and Autoimmunity

1998 • 26 citations